(Q37892162)

24 August 2017

1 reference

title

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review (English)

1 reference

24 August 2017

0 references

0 references

1 reference

1 reference

1 reference

1 reference

Alexandra M G Brunasso

1

1 reference

24 August 2017

Matteo Puntoni

2

1 reference

24 August 2017

Andrea Gulia

3

1 reference

24 August 2017

Cesare Massone

4

1 reference

24 August 2017

20 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

50

1 reference

24 August 2017

9

1 reference

24 August 2017

1700-1711

1 reference

Global epidemiology of hepatitis C virus infection

24 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Incidence and risk factors for psoriasis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Viral hepatitis and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Etanercept therapy in patients with autoimmunity and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Infliximab in the treatment of refractory vasculitis secondary to hepatitis C-associated mixed cryoglobulinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKER190

10.1093/RHEUMATOLOGY/KER190

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference